Complement Therapeutics Announces First Patient Dosed with CTx001 in the Phase I/II Opti-GAIN Study for Geographic Atrophy Secondary to AMD • First patient dosed in Opti-GAIN, a first-in-human Phase I/II clinical trial of CTx001 in Geographic Atrophy secondary to AMD
• CTx001 is an investigational AAV-based gene therapy designed to deliver mini-CR1, a potent modulator of mul...

CEO Q&A: Dr Ningfeng Fiona Li on Preventing the Side Effects of Cancer Treatment

“Cancer treatment should focus not only on fighting the disease, but also on helping patients maintain dignity, confidence and quality of life throughout their care.”~ Dr Li

Dr Ningfeng Fiona Li is the Founder and CEO of VasoDynamics, a biotechnology company developing medicine...